EGFR/HER2-IN-7 is a highly selective and potent anticancer compound designed to target MCF-7 breast cancer cells by functioning as a dual inhibitor of EGFR/HER2 kinases and DHFR (dihydrofolate reductase), with IC50 values of 0.18 μM for EGFR, 0.146 μM for HER2, and 0.907 μM for DHFR [1].

EGFR/HER2-IN-7 (compound 27) shows significant cytotoxicity with an IC50 of 10.81 μM against MCF-7 breast cancer cells and demonstrates notable anti-breast cancer properties with an IC50 of 8.29 μM after 72 hours. A Cell Viability Assay revealed that EGFR/HER2-IN-7, at concentrations up to 1 mM and a 72-hour incubation period, inhibited the growth of various cancer cell lines, including HepG2 hepatocellular carcinoma, MCF-7 breast cancer, HCT-116 colorectal carcinoma, PC-3 prostate, and HeLa cervical epithelioid carcinoma, with IC50 values of 10.81 μM, 8.29 μM, 13.78 μM, 16.63 μM, and 7.63 μM, respectively. Additionally, a Cell Cytotoxicity Assay using the normal healthy cell line WI-38 (fetal lung fibroblast cells) demonstrated low cytotoxicity and high IC50 values, indicating selective action towards cancer cells over healthy cells.